99 results
6-K
EX-99.1
SLGL
Sol-Gel Technologies Ltd
28 May 24
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
7:17am
substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution
424B3
SLGL
Sol-Gel Technologies Ltd
20 May 24
Prospectus supplement
4:05pm
revenue for the first quarter of 2023 was revised as reflected in the below income statement.
Research and development expenses were $5.3 million compared … financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we
6-K
EX-99.1
SLGL
Sol-Gel Technologies Ltd
20 May 24
Sol-Gel Reports First Quarter 2024 Financial Results and Provides
7:15am
, previously reported revenue for the first quarter of 2023 was revised as reflected in the below income statement.
Research and development expenses … substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution
6-K
EX-99.1
SLGL
Sol-Gel Technologies Ltd
16 May 24
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to
6:15am
) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory
424B3
SLGL
Sol-Gel Technologies Ltd
4 Apr 24
Prospectus supplement
9:05am
the Registered Direct Offering to fund the acquisition of SGT-610 and intend to use the balance of the net proceeds for research and development activities … , technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;
potential
6-K
EX-99.1
vxy7pb
1 Apr 24
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to
7:15am
POS AM
t7o9 8o9xyw1w
20 Mar 24
Prospectus update (post-effective amendment)
4:05pm
6-K
EX-99.1
6hvi4gqo
13 Mar 24
Sol-Gel Reports Full-Year 2023 Financial Results and 2023 - Corporate Highlights and Recent Developments
8:34am
6-K
EX-99.1
e9vd emavl2x
30 Nov 23
Current report (foreign)
7:10am
424B3
bruyh9yessh
9 Nov 23
Prospectus supplement
3:41pm
6-K
EX-99.1
uu85r7onu
9 Nov 23
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7:15am
424B3
e5t73tiai
10 Aug 23
Prospectus supplement
7:20am
6-K
EX-99.1
rmc3h7mycy9
10 Aug 23
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:10am
6-K
EX-99.2
up2hwe qqakp23xpo
10 Aug 23
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:10am
6-K
EX-99.1
xrxuwco9zjjuv3b3fjz
21 Jun 23
Notice of Annual Meeting of Shareholders
9:38am
6-K
EX-99.1
ath 0gj22
6 Jun 23
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to
7:15am
424B3
mk0yw6v8o9c4hv7d4
12 May 23
Prospectus supplement
9:15am
6-K
EX-99.1
a6u9xtta8lc
12 May 23
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides
12:00am
6-K
EX-99.1
9jkqy w5purf
21 Nov 22
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:42pm